Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Dyne Therapeutics Inc shares valued at $35,402 were sold by Cox John on Sep 05 ’25. At $13.41 per share, Cox John sold 2,640 shares. The insider’s holdings dropped to 199,539 shares worth approximately $2.49 million following the completion of this transaction.
Also, Friedl-Naderer Johanna sold 894 shares, netting a total of over 11,863 in proceeds. Following the sale of shares at $13.27 each, the insider now holds 95,017 shares.
Before that, Friedl-Naderer Johanna had sold 144 shares from its account. In a trade valued at $1,931, the Chief Commercial Officer traded Dyne Therapeutics Inc shares for $13.41 each. Upon closing the transaction, the insider’s holdings decreased to 144 shares, worth approximately $1.19 million.
As published in a research note from Raymond James on August 25, 2025, Dyne Therapeutics Inc [DYN] has been rated up from an Outperform to a Strong buy and the price target has been revised to $35. Analysts at Bernstein started covering the stock with ‘”a Mkt perform”‘ outlook in a report released in late June.
Analyzing DYN Stock Performance
On last trading session, Dyne Therapeutics Inc [NASDAQ: DYN] plunged -1.19% to $12.5. The stock’s lowest price that day was $12.44, but it reached a high of $13.07 in the same session. During the last five days, there has been a drop of approximately -5.09%. Over the course of the year, Dyne Therapeutics Inc shares have dropped approximately -63.05%. Shares of the company reached a 52-week high of $26.22 on 01/02/25 and a 52-week low of $6.36 on 04/09/25.
Support And Resistance Levels for Dyne Therapeutics Inc (DYN)
According to the 24-hour chart, there is a support level at 12.27, which, if violated, would cause prices to drop to 12.04. In the upper region, resistance lies at 12.90. The next price resistance is at 13.30. RSI (Relative Strength Index) is 46.50 on the 14-day chart, showing neutral technical sentiment.
Is Dyne Therapeutics Inc subject to short interest?
Stocks of Dyne Therapeutics Inc saw a sharp steep in short interest on 2025-09-15 dropping by -1.84 million shares to 15.3 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 17.14 million shares. A decline of -12.01% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.78 of the overall float, the days-to-cover ratio (short ratio) decline to 6.78.
Which companies own the most shares of Dyne Therapeutics Inc (DYN)?
In terms of Dyne Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 34.5 in the next 12 months, up nearly 172.73% from the previous closing price of $12.65. Analysts anticipate Dyne Therapeutics Inc stock to reach 35 by 2025, with the lowest price target being 34. In spite of this, 8 analysts ranked Dyne Therapeutics Inc stock as Buy at the end of 2025. On May 29, 2025, Evercore ISI assigned a price target of “an Outperform” to the stock and initiated coverage with a $46.
